Pneumonia, Ventilator-Associated Clinical Trial
Official title:
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation. Post-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR < 8000 AB/C All reported data about recombinant human IFNγ 1b for the control of secondary infections in patients with septic shock used the dose of 100 micrograms per day by subcutaneous route for 3 to 5 days . At this dose, no retrospective study has reported any serious adverse effects and recombinant human IFNγ 1b allows an increase in monocyte membrane expression of mHLA-DR.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06370598 -
Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia
|
Phase 1/Phase 2 | |
Terminated |
NCT02806141 -
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
|
Phase 3 | |
Completed |
NCT01765530 -
Efficacy Study of a Novel Device to Clean the Endotracheal Tube
|
N/A | |
Completed |
NCT00521677 -
Comparison Between Two Methods of Oral Care on the Incidence of VAP
|
N/A | |
Completed |
NCT00529776 -
Prophylaxis of Ventilator Associated Pneumonia by Continuous Lateral Rotation Therapy
|
N/A | |
Completed |
NCT03401463 -
Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar
|
N/A | |
Completed |
NCT02950519 -
Endotracheal Tube Cuff Pressures in Ventilated Patients
|
N/A | |
Completed |
NCT01875692 -
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
|
N/A | |
Completed |
NCT00515034 -
A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
|
Phase 2 | |
Recruiting |
NCT05117125 -
Biomarkers for Ventilator-associated Pneumonia
|
||
Completed |
NCT04755972 -
Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2
|
N/A | |
Terminated |
NCT02940626 -
Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.
|
Phase 2 | |
Completed |
NCT01577862 -
Colistin and Rifampicin for MDR-Acinetobacter
|
Phase 3 | |
Completed |
NCT00572559 -
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
|
Phase 4 | |
Withdrawn |
NCT04566172 -
Preoperative Optimization to Improve Functional Status
|
N/A | |
Recruiting |
NCT04215692 -
Lung Ultrasound-guided Fluid Therapy in Pediatric Intensive Care Unit Patients
|
N/A | |
Completed |
NCT03816956 -
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
|
Phase 3 | |
Active, not recruiting |
NCT01123681 -
Intubation and Extubation Over 48 Hours Mechanical Ventilation
|
N/A | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03527992 -
Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia
|
N/A |